<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Article Tag Suite 1.1//EN"
  "https://jats.nlm.nih.gov/publishing/1.1/JATS-journalpublishing1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink"
         xmlns:mml="http://www.w3.org/1998/Math/MathML"
         article-type="research-article"
         xml:lang="en">
  <front>
    <journal-meta>
      <journal-title-group>
        <journal-title>American Journal of Pharmacy and Health Research</journal-title>
        <abbrev-journal-title abbrev-type="publisher">AJPHR</abbrev-journal-title>
      </journal-title-group>
      <issn pub-type="epub">2321-3647</issn>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="doi">10.46624/ajphr.2020.v8.i6.001</article-id>
      <article-id pub-id-type="publisher-id">AJPHR806001</article-id>
      <title-group>
        <article-title>Psoriasis pathogenesis and current treatment: A Review</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Kumar</surname>
            <given-names>Rohit </given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Pathak</surname>
            <given-names>DP</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Sahoo</surname>
            <given-names>PK</given-names>
          </name>
        </contrib>
      </contrib-group>
      <pub-date pub-type="epub" iso-8601-date="2020-06-01">
        <month>06</month>
        <day>01</day>
        <year>2020</year>
      </pub-date>
      <volume>8</volume>
      <issue>6</issue>
      <abstract>
        <p>ABSTRACTPsoriasis is a multi-factorial skin disease with a complex pathogenesis. Various factors which have been suggested to play a key role in the pathogenesis are T cells, antigen presenting cells (APC&apos;s), keratinocytes, Langerhans&apos; cells, macrophages, natural killer cells, an array of Th1 type cytokines. The age of onset, chronicity, physical, and psychosocial consequences of the disease cause psoriasis to have a significant impact on patient quality of life. Scalp psoriasis is no different, and effective treatment results in an improvement in quality of life. Successful management of scalp psoriasis includes topical therapies that are acceptable to the patient for mild-to-moderate disease, and systemic therapies for recalcitrant or moderate-to-severe disease. The factors influencing psoriasis severity, the indications for systemic treatments, the overall parameters to be considered in the treatment choice, life style interventions, and the recommendations for the use, screening, and monitoring of systemic therapies available including acitretin, cyclosporine, methotrexate, apremilast, adalimumab, etanercept, infliximab. Keywords: Psoriasis, pathogensis, systemic therapies</p>
      </abstract>
      <kwd-group kwd-group-type="author">
        <kwd>Psoriasis</kwd>
        <kwd>pathogensis</kwd>
        <kwd>systemic therapies</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <!-- Full article body not available in metadata-only JATS export. See PDF/HTML galley. -->
  </body>
  <back/>
</article>
